Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06956274 · ClinicalTrials.gov registry record
Ostomy Readmission Reduction Program
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Not yet
- Registry status
- 40
- Enrollment target
NCT06956274: Clinical Trial study, sponsored by Cedars-Sinai Medical Center.
NCT06956274 is a clinical trial that has not yet begun recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06956274 has not yet begun recruiting, sponsored by Cedars-Sinai Medical Center.
- NOT YET RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to reduce complications like peristomal skin issues, stoma-related problems, dehydration, and other preventable factors that can lead to re-hospitalization within the first 30 days after surgery.
Primary Outcome
The proportion of participants who are readmitted to the hospital within 30 days following surgery. Readmissions will be evaluated for any reason, including complications, adverse events, or recovery issues that necessitate hospitalization after the initial surgical procedure.
Interventions
- OTHER Preoperative Telehealth
- OTHER Measure Ostomy Output
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-12-01 |
What is known before NCT06956274 opens enrollment
NCT06956274 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Preoperative Telehealth is the first listed.
NCT06956274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06956274 about?
NCT06956274 is a clinical study titled "Ostomy Readmission Reduction Program". The purpose of this study is to reduce complications like peristomal skin issues, stoma-related problems, dehydration, and other preventable factors that can lead to re-hospitalization within the first 30 days after surgery.
What is the current status of trial NCT06956274?
This trial is currently not yet recruiting. The enrollment target is 40 participants. The study started on 2025-05-01. Estimated completion is 2026-12-01.
What interventions are being tested in trial NCT06956274?
The interventions under investigation include: Preoperative Telehealth (OTHER), Measure Ostomy Output (OTHER).
Who is sponsoring clinical trial NCT06956274?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI